文献速递眼底病与葡萄膜炎

三种视网膜病变玻璃体腔抗VEGF药物疗效与危害比较

Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis.
PubMed 文献 · Br J Ophthalmol · 2018-11-08

系统评价17项试验,比较阿柏西普、贝伐珠单抗和雷珠单抗在新生血管性年龄相关性黄斑变性(NVAMD)、糖尿病性黄斑水肿(DME)和视网膜静脉阻塞(RVO)中对最佳矫正视力(BCVA)、生活质量及不良事件的影响。结果显示各药物间视力增益无临床重要差异(≥5个字母),眼部和全身不良事件发生率低且组间相似;两项试验中阿柏西普和雷珠单抗的成本效果显著低于再包装贝伐珠单抗。

要点

  • 17项试验均未报告药物间视力增益的临床重要差异(≥5个字母)。
  • 9项试验提供高强度证据表明贝伐珠单抗与雷珠单抗在NVAMD中无差异。
  • 3项试验提供中等强度证据表明贝伐珠单抗与雷珠单抗在DME中无差异。

核心结论

  • 总体而言,没有一种抗VEGF药物在有效性或安全性上明显优于另一种。
  • 阿柏西普和雷珠单抗在两项试验中的成本效果显著低于再包装贝伐珠单抗。

研究设计与样本

  • 系统评价与荟萃分析,检索截至2017年2月的已发表和未发表文献。
  • 纳入随机对照试验及报告美国比较成本的队列或模型研究,共17项试验。
  • 两名评价者提取数据并使用既定方法分级证据强度。

主要发现

  • 17项纳入试验均未报告药物间视力增益的临床重要差异(≥5个字母)。
  • 9项试验提供高强度证据表明贝伐珠单抗与雷珠单抗在NVAMD中无差异。
  • 3项试验提供中等强度证据表明贝伐珠单抗与雷珠单抗在DME中无差异。
  • 低强度证据表明阿柏西普与雷珠单抗在NVAMD、阿柏西普与贝伐珠单抗在RVO以及三种药物在DME中效果相似。
  • 眼部不良事件发生率低,全身危害组间总体相似,但1项DME试验报告雷珠单抗相比阿柏西普动脉血栓事件更多。

关键数值与推荐

  • 临床重要差异定义为视力增益≥5个字母。
  • 贝伐珠单抗与雷珠单抗在RVO中的比较证据不足。

临床怎么用

  • 选择抗VEGF药物时可综合考虑有效性、安全性和成本效果。
  • 再包装贝伐珠单抗在成本效果上可能优于阿柏西普和雷珠单抗。

局限性

  • 贝伐珠单抗与雷珠单抗在RVO中的比较证据不足。
  • 部分比较的证据强度为低强度或中等强度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Intravitreal antivascular endothelial growth factor (VEGF) agents are widely used to treat ocular conditions but the benefits and harms of these treatments are uncertain. We conducted a systematic review to compare the effects of aflibercept, bevacizumab and ranibizumab on best-corrected visual acuity (BCVA) changes, quality of life and ocular or systemic adverse events in patients with neovascular age-related macular degeneration (NVAMD), diabetic macular oedema (DME) and central or branch retinal vein occlusion (RVO). We searched published and unpublished literature sources to February 2017 for randomised controlled trials and cohort or modelling studies reporting comparative costs in the USA. Two reviewers extracted data and graded the strength of the evidence using established methods. Of 17 included trials, none reported a clinically important difference (≥ 5 letters) in visual acuity gains between agents. Nine trials provide high-strength evidence of no difference between bevacizumab and ranibizumab for NVAMD. Three trials provide moderate-strength evidence of no difference between bevacizumab and ranibizumab for DME. There was low-strength evidence of similar effects between aflibercept and ranibizumab for NVAMD, aflibercept and bevacizumab for RVO and all three agents for DME. There was insufficient evidence to compare bevacizumab and ranibizumab for RVO. Rates of ocular adverse events were low, and systemic harms were generally similar between groups, although 1 DME trial reported more arterial thrombotic events with ranibizumab versus aflibercept. Overall, no agent had a clear advantage over another for effectiveness or safety. Aflibercept and ranibizumab were significantly less cost-effective than repackaged bevacizumab in two trials. Systematic review registration number: CRD42016034076.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Low A, Faridi A, Bhavsar KV, et al. Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis. Br J Ophthalmol. 2018. PMID: 30409915. doi:10.1136/bjophthalmol-2018-312691

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。